169 related articles for article (PubMed ID: 1671875)
1. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
[TBL] [Abstract][Full Text] [Related]
2. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
3. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
Piro LD; Carrera CJ; Carson DA; Beutler E
N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
[TBL] [Abstract][Full Text] [Related]
4. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
6. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
Tefferi A; Witzig TE; Reid JM; Li CY; Ames MM
J Clin Oncol; 1994 Mar; 12(3):569-74. PubMed ID: 8120555
[TBL] [Abstract][Full Text] [Related]
9. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.
Betticher DC; Zucca E; von Rohr A; Egger T; Radford JA; Ambrosetti A; Bürki K; Rufener B; Schmitz SF; Cerny T
Ann Oncol; 1996 Oct; 7(8):793-9. PubMed ID: 8922192
[TBL] [Abstract][Full Text] [Related]
10. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.
Carrera CJ; Yamanaka H; Piro LD; Lotz M; Carson DA
Adv Exp Med Biol; 1989; 253B():219-25. PubMed ID: 2575348
[TBL] [Abstract][Full Text] [Related]
11. [2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research].
Sperb RA; von Rohr A; Ratschiller D; Bacchi M; Tichelli A; Hess U; Cerny T; Tobler A; Betticher DC
Schweiz Med Wochenschr; 1998 Oct; 128(42):1593-7. PubMed ID: 9824888
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
Vahdat L; Wong ET; Wile MJ; Rosenblum M; Foley KM; Warrell RP
Blood; 1994 Nov; 84(10):3429-34. PubMed ID: 7949097
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592
[No Abstract] [Full Text] [Related]
14. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Estey EH; Kurzrock R; Kantarjian HM; O'Brien SM; McCredie KB; Beran M; Koller C; Keating MJ; Hirsch-Ginsberg C; Huh YO
Blood; 1992 Feb; 79(4):882-7. PubMed ID: 1346577
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials referral resource. Clinical trials with 2-chlorodeoxyadenosine.
Cheson BD
Oncology (Williston Park); 1992 May; 6(5):95-8. PubMed ID: 1350917
[No Abstract] [Full Text] [Related]
17. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F
Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: a report of the Children's Cancer Group.
Ettinger LJ; Ivy P; Gaynon PS; Ettinger AG; Liu-Mares W; Krailo MD
Cancer; 1997 Jul; 80(2):311-6. PubMed ID: 9217045
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
